Investors Encouraged to Join Class Action Against Regeneron Pharmaceuticals by Deadline
The Gross Law Firm has issued an important notice directed to shareholders of Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN), a renowned biotechnology company. This advisory highlights the opportunity for affected investors to join a class action lawsuit aimed at seeking justice for financial losses incurred due to alleged illicit activities by the company. If you purchased shares of Regeneron during the specified class period, which runs from November 2, 2023, to October 30, 2024, you are encouraged to reach out to the Gross Law Firm to explore the option of being appointed as a lead plaintiff. It’s important to note that participating in the recovery process does not necessitate becoming a lead plaintiff.
The backdrop of this lawsuit involves significant allegations against Regeneron Pharmaceuticals, primarily focusing on how the company purportedly misled investors through a series of erroneous and misleading statements. The core of the allegations maintains that Regeneron was involved in practices that included:
1. Making undisclosed payments of credit card fees to distributors with the stipulation that they would not charge customers higher prices on Eylea, one of the company's main products, when using credit cards.
2. These payments resulted in artificially subsidized prices accessible to customers buying Eylea with credit cards.
3. Regeneron ostensibly provided price concessions, which subsequently lowered the selling price of Eylea.
4. As retina practices are particularly price-sensitive toward credit card purchases of anti-VEGF medications, these price concessions by Regeneron rendered the company's offerings more competitive.
5. Consequently, these practices led to artificially inflated sales figures for Eylea.
6. Furthermore, Regeneron's failure to disclose these critical financial maneuvers alongside its misleading positive statements about the company's financial health raises severe concerns.
Interested shareholders are urged to register their information immediately to avoid missing the impending deadline: March 10, 2025. This deadline is critical for those seeking to join the class action, as registration ensures that affected investors receive regular updates throughout the litigation process. The Gross Law Firm guarantees that there are no costs nor obligations associated with participating.
The Gross Law Firm is recognized nationally for representing investors in class actions, determined to safeguard the rights of individuals impacted by deceitful practices in the corporate world. Their commitment to holding companies accountable for fraudulent behaviors that harm investors is steadfast, further emphasizing their dedication to upholding ethical business conduct.
To take part in this class action process, shareholders who acquired Regeneron's stocks during the stipulated timeframe are invited to reach out via the provided link to submit their information. The link connects to a submission form specifically designed for this purpose: Class Action Submission Form.
The law firm's office is conveniently located at 15 West 38th Street, 12th Floor, New York, NY, 10018. For direct inquiries, potential plaintiffs can contact the firm at (646) 453-8903 or via email at [email protected] By joining together through this legal action, investors can unite against what they believe to be unethical business practices, potentially recovering their losses and sending a message of accountability in the financial industry.
Allegations Against Regeneron
The backdrop of this lawsuit involves significant allegations against Regeneron Pharmaceuticals, primarily focusing on how the company purportedly misled investors through a series of erroneous and misleading statements. The core of the allegations maintains that Regeneron was involved in practices that included:
1. Making undisclosed payments of credit card fees to distributors with the stipulation that they would not charge customers higher prices on Eylea, one of the company's main products, when using credit cards.
2. These payments resulted in artificially subsidized prices accessible to customers buying Eylea with credit cards.
3. Regeneron ostensibly provided price concessions, which subsequently lowered the selling price of Eylea.
4. As retina practices are particularly price-sensitive toward credit card purchases of anti-VEGF medications, these price concessions by Regeneron rendered the company's offerings more competitive.
5. Consequently, these practices led to artificially inflated sales figures for Eylea.
6. Furthermore, Regeneron's failure to disclose these critical financial maneuvers alongside its misleading positive statements about the company's financial health raises severe concerns.
Importance of Registration
Interested shareholders are urged to register their information immediately to avoid missing the impending deadline: March 10, 2025. This deadline is critical for those seeking to join the class action, as registration ensures that affected investors receive regular updates throughout the litigation process. The Gross Law Firm guarantees that there are no costs nor obligations associated with participating.
The Mission of the Gross Law Firm
The Gross Law Firm is recognized nationally for representing investors in class actions, determined to safeguard the rights of individuals impacted by deceitful practices in the corporate world. Their commitment to holding companies accountable for fraudulent behaviors that harm investors is steadfast, further emphasizing their dedication to upholding ethical business conduct.
How to Participate
To take part in this class action process, shareholders who acquired Regeneron's stocks during the stipulated timeframe are invited to reach out via the provided link to submit their information. The link connects to a submission form specifically designed for this purpose: Class Action Submission Form.
Legal Assistance Information
The law firm's office is conveniently located at 15 West 38th Street, 12th Floor, New York, NY, 10018. For direct inquiries, potential plaintiffs can contact the firm at (646) 453-8903 or via email at [email protected] By joining together through this legal action, investors can unite against what they believe to be unethical business practices, potentially recovering their losses and sending a message of accountability in the financial industry.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.